Sharp Laboratories of America, Inc

Sharp Kabushiki Kaisha Corporation

Other

Sirnaomics, Inc.

Sharp Microelectronics Technology, Inc.

Xenogenic Development Limited Liability Company

David R Evans

Sheng Teng Hsu

Wei-Wei Zhuang

Wei Pan

Tingkai Li

Jong-Jan Lee

Tue H Nguyen

Douglas James Tweet

Yuhao Lu

Lawrence J Charneski

Yoshi Ono

Jer-shen Maa

Bruce Dale Ulrich

Fengyan Zhang

Yanjun Ma

Hidayat Kisdarjono

Sean Vail

Patrick Y Lu

Allen Burmaster

John Xu

John F Conley, Jr

Lisa Stecker

Robert A Barrowcliff

John Hartzell

Wei Gao

Long Wang

Vera Simonenko

Hongning Yang

Masayuki Tajiri

Alan Y Lu

Jun Xu

Akinori Hashimura

Jong Jan Lee

Liang Tang

Nobuyoshi Awaya

Tingkal Li

Greg Michael Stecker

Patricia Evans

Yibin Cai

Qing Ge

The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection

An alkali/oxidant battery is provided with an associated method of creating battery capacity. The battery is made from an anode including a reduced first alkali metal such as lithium (Li), sodium (Na), and potassium (K), when the battery is charged. The battery's catholyte includes an element, in the battery charged state, such as nickel oxyhydroxide (NiOOH), manganese(IV) (oxide MnO), or iron(III) oxyhydroxide Fe(OH)), with the alkali metal hydroxide. An alkali metal ion permeable separator is interposed between the anolyte and the catholyte. For example, if the catholyte includes nickel(II) hydroxide (Ni(OH)) in a battery discharged state, then it includes NiOOH in a battery charged state. To continue the example, the anolyte may include dissolved lithium ions (Li) in a discharged state, with solid phase reduced Li formed on the anode in the battery charged state.

Alkali/oxidant battery

A method is provided for forming a metal/semiconductor/metal (MSM) back-to-back Schottky diode from a silicon (Si) semiconductor. The method deposits a Si semiconductor layer between a bottom electrode and a top electrode, and forms a MSM diode having a threshold voltage, breakdown voltage, and on/off current ratio. The method is able to modify the threshold voltage, breakdown voltage, and on/off current ratio of the MSM diode in response to controlling the Si semiconductor layer thickness. Generally, both the threshold and breakdown voltage are increased in response to increasing the Si thickness. With respect to the on/off current ratio, there is an optimal thickness. The method is able to form an amorphous Si (a-Si) and polycrystalline Si (polySi) semiconductor layer using either chemical vapor deposition (CVD) or DC sputtering. The Si semiconductor can be doped with a Group V donor material, which decreases the threshold voltage and increases the breakdown voltage.

Back-to-back metal/semiconductor/metal (MSM) Schottky diode

The present invention relates to compositions and methods for development of resistance-proof siRNA therapeutics for prevention and treatment of influenza viral infections. The compositions include a pharmaceutical composition comprising siRNA molecules that target conserved regions of an influenza virus gene and a pharmaceutically acceptable polymeric carrier. In one embodiment, the polymeric carrier condenses the molecules to form a nanoparticle.

Compositions and methods for 'resistance-proof' SiRNA therapeutics for influenza

A battery and an associated method are provided for generating power using an air cathode battery with a slurry anode. The method provides a battery with an air cathode separated from an anode current collector by an electrically insulating separator and an extrusion gap. The anode current collector extruder has a first plate with a plurality of slurry outlet perforations, and a sleeve having a first partition immediately adjacent to the extruder first plate, with a plurality of slurry inlet perforations. Active slurry is provided under pressure to an extruder inlet, and the extruder first plate slurry outlet perforations are selectively aligned with sleeve first partition slurry inlet perforations. Active slurry deposits are formed in the extrusion gap to mechanically charge the battery. In the discharge position, the sleeve moves so that the perforations no longer align, and slurry in the extruder is isolated from slurry in the extrusion gap.

Large-scale metal-air battery with slurry anode

A transition metal hexacyanoferrate (TMH) cathode battery is provided. The battery has a AMn[Fe(CN)].zHO cathode, where the A cations are either alkali or alkaline-earth cations, such as sodium or potassium, where x is in the range of 1 to 2, where y is in the range of 0.5 to 1, and where z is in the range of 0 to 3.5. The AMn[Fe(CN)].zHO has a rhombohedral crystal structure with Mnand Fehaving the same reduction/oxidation potential. The battery also has an electrolyte, and anode made of an A metal, an A composite, or a material that can host A atoms. The battery has a single plateau charging curve, where a single plateau charging curve is defined as a constant charging voltage slope between 15% and 85% battery charge capacity. Fabrication methods are also provided.

Transition metal hexacyanoferrate battery with carbonaceous anode

The present invention provides compositions and methods for using combinations of TGF&#x3b2;1 and Cox-2 inhibitors and TGF&#x3b2;1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGF&#x3b2;1 and Cox-2 at the same time, resulting in significant less scar formation.

Combinations of TGF&#x3b2; and COX-2 inhibitors and methods for their therapeutic application

An air cathode battery is provided that uses a zinc slurry anode with carbon additives. The battery is made from an air cathode and a zinc slurry anode. The zinc slurry anode includes zinc particles, an alkaline electrolyte, with a complexing agent and carbon additives in the alkaline electrolyte. A water permeable ion-exchange membrane and electrolyte chamber separate the zinc slurry from the air cathode. The carbon additives may, for example, be graphite, carbon fiber, carbon black, or carbon nanoparticles. The proportion of carbon additives to zinc is in the range of 2.5 to 10% by weight. The proportion of alkaline electrolyte in the zinc slurry is in the range of 50 to 80% by volume.

Air cathode battery using zinc slurry anode with carbon additive

A protected transition metal hexacyanoferrate (TMHCF) battery cathode is presented, made from AMFe(CN).mHO particles, where the A cations are either alkali or alkaline-earth cations, and M is a transition metal. In one aspect the cathode pas tion layer may be materials such as oxides, simple salts, carbonaceous materials, or polymers that form a film overlying the AMFe(CN).mHO particles. In another aspect, the cathode passivation layer is a material such as oxygen, nitrogen, sulfur, fluorine, chlorine, or iodine that interacts with the AMFe(CN).mHO particles, to cure defects in the AMFe(CN).mHO crystal lattice structure. Also presented are TMHCF battery synthesis methods.

Protected transition metal hexacyanoferrate battery electrode synthesis method

The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.

SiRNA compositions and methods for treatment of HPV and other infections

A method is provided for forming a rechargeable metal-ion battery with a non-aqueous hybrid ion electrolyte. The method provides a transition metal hexacyanometallate (TMHCM) cathode (AM1M2(CN)HO), where 'A' is from a first group of metals, and M1 and M2 are transition metals. The electrolyte includes a first type of cation from the first group of metals, different than 'A'. The method connects the cathode and anode to external circuitry to perform initial charge/discharge operations. As a result, a hybrid ion electrolyte is formed including the first type of cation and &#x201c;A&#x201d; cations. Subsequently, cations are inserted into the anode during charging, which alternatively may be only &#x201c;A&#x201d; cations, only the first type of cation, or both the &#x201c;A&#x201d; cations and the first type of cation. Only &#x201c;A&#x201d; cations, only the first type, or both &#x201c;A&#x201d; and the first type of cation are inserted into the TMHCM during discharge.

Rechargeable metal-ion battery with non-aqueous hybrid ion electrolyte

Transition metal hexacyanoferrate battery with single plateau charge/discharge curve

A protected transition metal hexacyanoferrate (TMHCF) battery cathode is presented, made from AMFe(CN).mHO particles, where the A cations are either alkali or alkaline-earth cations, and M is a transition metal. In one aspect the cathode passivation layer may be materials such as oxides, simple salts, carbonaceous materials, or polymers that form a film overlying the AMFe(CN).mHO particles. In another aspect, the cathode passivation layer is a material such as oxygen, nitrogen, sulfur, fluorine, chlorine, or iodine that interacts with the AMFe(CN).mHO particles, to cure defects in the AMFe(CN).mHO crystal lattice structure. Also presented are TMHCF battery synthesis methods.

Protected transition metal hexacyanoferrate battery electrode

A transition metal hexacyanoferrate (TMHCF) battery electrode is provided with a Fe(CN)additive. The electrode is made from AMFe(CN).mHO particles overlying a current collector, where the A cations are either alkali and alkaline-earth cations such as sodium (Na), potassium (K), calcium (Ca), or magnesium (Mg), and M is a transition metal. A Fe(CN)additive modifies the AMFe(CN).mHO particles. The Fe(CN)additive may be ferrocyanide ([Fe(CN)]) or ferricyanide ([Fe(CN)]). Also provided are a related TMHCF battery with Fe(CN)additive, TMHCF fabrication process, and TMHCF battery fabrication process.

Hexacyanoferrate battery electrode modified with ferrocyanides or ferricyanides

Transition metal hexacyanoferrate battery cathode with single plateau charge/discharge curve

Growing community of inventors

Beaverton, OR, United States of America

David R Evans